The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer
Official Title: Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Lung Cancer
Study ID: NCT03501056
Brief Summary: This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced lung cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for lung cancer.
Detailed Description: Primary pulmonary carcinoma is one of the most common malignancies in China, ranking first in all malignant tumors and mortality.Immunetherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single- center, The investigators plan to recruit for 90 patients with advanced lung cancer,and all patients are divided into three groups.one group will receive cryotherapy, one group will receive conventional therapy,and the rest one will receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy. The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Institutional Review Board of Guangzhou Fuda Cancer Hospital, Guangzhou, Guangdong, China
Name: Jibing Chen, Doctor
Affiliation: Guangzhou Fuda Cancer Hospital
Role: STUDY_CHAIR